CLL.L Regulatory News (CLL)

 5 May 2020

Cello Health plc

("Cello" or the "Company")

Issue of Equity

Further to the announcement released on 1 February 2017 regarding the acquisition of the assets of Defined Healthcare Research, Inc, and Cancer Progress, LLC ("Defined Health") by the Company, Cello today announces that the final deferred consideration payments to the vendors of Defined Health have now been settled, and the maximum deferred consideration has been achieved.

To satisfy the equity element of the final instalment of the deferred consideration, the Company has applied for the admission of 194,391 new ordinary shares of 10 pence each in the Company ("Ordinary Shares") to trading on AIM, which is expected to occur on 11 May 2020.

Following admission, Cello's issued share capital will consist of 107,143,531 Ordinary Shares, of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company will therefore be 106,690,531 Ordinary Shares.

The above figure (106,690,531 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

About Cello Health plc

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading scientific, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia, New Jersey, London, Edinburgh, and Farnham.

For further information, please visit: https://cellohealthplc.com